The X-Ray Reinvented
Our proprietary, advanced emitter technology platform – Quastar® produces high output and high quality photons more efficiently allowing our partners to improve our quality of life.


Life, it matters to us.
Rad Source irradiator solutions impact the lives of people across the world daily. From improving transplant patient outcomes, advancing cancer and cell research or helping control populations of disease-carrying and crop-destroying insects – Life matters.
What’s the Difference?
Quastar® vs. Traditional X-ray Imaging Tube
When it comes to x-ray field output, beam hardness, uniformity and versatility, the Quastar x-ray emitter is second to none. Quastar’s proprietary technology provides the ability to produce a greater photon flux of higher energy x-rays while filtering the weak x-rays that cause uneven dose treatment.
Quastar’s engineering provides faster, higher quality, and more uniform dosing of the target than the standard imaging tube, and it does so more efficiently.
What’s the Difference?
Quastar vs. Nuclear
Although a reactive source, nuclear radiation has been around for years due to its ease of availability. As technology matured, experts understood and acted on the effects of gamma ionizing radiation. From its volatility to harmful byproducts and stringent licensing requirements, gamma irradiation is becoming a thing of the past.
The Department of Energy has spearheaded CIRP (Cesium Irradiator Replacement Program) – a subsidizing initiative created to replace gamma isotope-source (cesium-137 based) irradiators in the US. They provide an up-to 50% financial incentive towards the purchase of a new non-radio isotopic device as well as the removal and disposal of current irradiator – an approximate cost-reduction of more than $200 thousand dollars.
By 2025, gamma powered irradiators will become obsolete. Stay ahead of the inevitable with us as we propel our global partners to improve and enhance the quality of life.
Latest News & Studies
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs
Emerging evidence indicates that ionizing radiation (IR) and chemotherapy activate Type I interferon (IFN) signaling in tumor and host cells. However, the mechanism of induction is poorly understood. We identified a novel...
Cathepsin B and uPAR regulate self-renewal of glioma-initiating cells through GLI-regulated Sox2 and Bmi1 expression
Cancer-initiating cells comprise a heterogeneous population of undifferentiated cells with the capacity for self-renewal and high proliferative potential. We investigated the role of uPAR and cathepsin B in the maintenance of...
Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD)
Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation (BMT). Upregulation of inflammatory cytokines precedes the clinical presentation of GVHD and predicts its severity. In this...